| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -37,059 | -21,255 |
| Interest on debt instrument | 0 | 0 |
| Stock-based compensation | 14,373 | 8,751 |
| Prepaid expenses and other current assets | 1,606 | -1,440 |
| Accounts payable | 2,452 | -2,595 |
| Accrued liabilities | -545 | 429 |
| Net cash used in operating activities | -22,385 | -13,230 |
| Net cash provided by investing activities | 0 | 0 |
| Proceeds from issuance of warrants and pre-funded warrants, net of issuance costs | 23,216 | 23,216 |
| Proceeds from the exercise of warrants and pre-funded warrants | 3,687 | 625 |
| Payments on short-term note | 0 | 0 |
| Net cash provided by financing activities | 26,903 | 23,841 |
| Net change in cash and cash equivalents | 4,518 | 10,611 |
| Cash and cash equivalents at beginning of period | 94,851 | - |
| Cash and cash equivalents at end of period | 99,369 | - |
TENAX THERAPEUTICS, INC. (TENX)
TENAX THERAPEUTICS, INC. (TENX)